Sun, Sep 21, 2014, 2:42 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

gunslinger256 3 posts  |  Last Activity: Jul 12, 2014 12:23 PM Member since: Dec 15, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    BioTech I follow

    by atomsmith Jul 8, 2014 12:37 PM
    gunslinger256 gunslinger256 Jul 10, 2014 9:40 PM Flag

    I learned a long time ago to diversify my holdings away from IMGN. I still have a large position, but I make my money on other things.

    Sentiment: Buy

  • gunslinger256 by gunslinger256 Jul 10, 2014 9:50 PM Flag

    did anyone else notice that IMGN has quietly dropped the "Tap" platform name and adopted "ADC" naming convention?

    it doesn't strike me as something a leader in the field would do.

    Sentiment: Buy

  • Reply to

    Royalty stream kadcyla

    by gunter.strobel Jul 12, 2014 7:55 AM
    gunslinger256 gunslinger256 Jul 12, 2014 12:23 PM Flag

    no new information has been divulged by the companies around this agreement. End of royalty stream is still roughly 10-11 years away.

    it's not clear if royalty streams end for all products at once or if they end with each indication's approval.

    ie breast cancer approval in a 2nd line setting was approved in feb 2014 and the royalty stream has started.

    if gastric cancer is approved in 2016 do royalties for that end 25 years from 2016? and does breast cancer from first line therapy get it's own 25 year royalty stream?

    I would hope IMGN can get a wholly owned drug to approvals within the next 5 years and won't be dependent on kadcyla royalties.

    Sentiment: Buy

IMGN
11.35+0.01(+0.09%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.